Dr. Reddy's Lab

₹4685 37.1 | 0.8%

WEBSITE BSE:500124 NSE : DR.REDDY'S 09 Jun, 12:37

Market Cap ₹77992 Cr.

Stock P/E 17.3

P/B 3.4

Current Price ₹4685

Book Value ₹ 1398.2

Face Value 5

52W High ₹4987

Dividend Yield 0.85%

52W Low ₹ 3996.1

Edit Ratio

Dr. Reddy's Lab Research see more...

Overview Inc. Year: 1984Industry: Pharmaceuticals & Drugs

Dr. Reddy's Laboratories Limited is an India-based pharmaceutical corporation. The Company's segments consist of Global Generics, which is engaged in production and marketing prescription and over the counter finished pharmaceutical merchandise ready for consumption by patient, marketed under a brand name (branded formulations) or as usual finished dosages with healing equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and advertising and marketing active pharmaceutical elements and intermediates for finished pharmaceutical merchandise; Proprietary Products, which focuses on studies and development of differentiated formulations and Others, which includes the Company's absolutely-owned subsidiary, Aurigene Discovery Technologies Ltd, which is a discovery stage biotechnology organisation growing novel and treatments in the fields of oncology and inflammation.

Dr. Reddy's Lab Share Price

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Dr. Reddy's Lab Quarterly Results

#(Fig in Cr.)	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023
Net Sales	4942	4768	4945	5787	5338	5475	5233	6332	6790	6315
Other Income	71	83	108	206	56	122	854	41	59	139
Total Income	5012	4851	5053	5992	5394	5597	6087	6373	6849	6454
Total Expenditure	4403	3715	4211	4427	4123	5024	4292	4433	4851	4781
Operating Profit	610	1136	842	1565	1272	573	1795	1940	1997	1672
Interest	19	30	19	23	22	32	35	31	42	35
Depreciation	311	309	284	294	294	293	302	309	324	316
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	280	797	539	1248	956	248	1459	1600	1632	1322
Provision for Tax	267	258	175	277	265	162	279	499	394	369
Profit After Tax	13	539	364	971	691	87	1180	1100	1238	953
Adjustments	15	18	17	25	19	11	9	14	6	8
Profit After Adjustments	28	557	380	996	709	97	1189	1114	1244	960
Adjusted Earnings Per Share	1.7	33.5	22.9	59.8	42.6	5.8	71.5	67	74.7	57.6

Dr. Reddy's Lab Profit & Loss

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	TTM
Net Sales	9815	11896	13415	15023	15568	14196	14281	15448	17517	19048	21545	24670
Other Income	132	154	196	275	295	172	155	338	621	291	485	1093
Total Income	9947	12050	13611	15298	15863	14368	14436	15786	18138	19339	22030	25763
Total Expenditure	7375	9176	10165	11530	11983	11724	11930	12270	15047	15178	17778	18357
Operating Profit	2572	2874	3446	3769	3880	2644	2506	3516	3091	4161	4252	7404
Interest	114	104	153	109	83	63	79	89	98	97	96	143
Depreciation	518	550	648	760	939	1027	1077	1135	1163	1229	1165	1251
Exceptional Income / Expenses	-135	-54	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	1804	2165	2646	2900	2859	1554	1350	2336	1886	2884	3061	6013
Provision for Tax	504	638	683	563	751	297	438	386	-140	932	879	1541
Profit After Tax	1301	1527	1963	2336	2108	1257	912	1950	2026	1952	2183	4471
Adjustments	0	0	0	0	23	35	34	0	0	0	0	37
Profit After Adjustments	1301	1527	1963	2336	2131	1292	947	1950	2026	1952	2183	4507
Adjusted Earnings Per Share	76.7	89.9	115.3	137.1	124.9	77.9	57	117.5	121.9	117.3	131.2	270.8

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	13%	12%	9%	8%
Operating Profit CAGR	2%	7%	10%	5%
PAT CAGR	12%	4%	12%	5%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	8%	4%	18%	8%
ROE Average	12%	13%	12%	18%
ROCE Average	15%	14%	13%	17%

Dr. Reddy's Lab Balance Sheet

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Shareholder's Funds	4989	6369	7865	9853	12570	12262	12572	14024	15599	17642	19212
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	1642	1266	2076	1432	1069	545	2509	2200	130	630	575
Other Non-Current Liabilities	-32	19	107	247	-192	-89	30	-87	-938	-827	-1083
Total Current Liabilities	4591	5659	5790	6821	6347	8420	6894	5897	7214	8104	9766
Total Liabilities	11190	13313	15838	18353	19794	21138	22004	22034	22005	25548	28470
Fixed Assets	3412	4051	4641	5377	6563	6931	6968	7191	6850	8206	8122
Other Non-Current Assets	780	736	871	1099	1437	4524	4537	3733	2556	2792	2560
Total Current Assets	6999	8527	10326	11877	11794	9684	10498	11110	12599	14535	17788
Total Assets	11190	13313	15838	18353	19794	21138	22004	22034	22005	25548	28470

Dr. Reddy's Lab Cash Flow

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Opening Cash & Cash Equivalents	573	736	520	862	540	492	378	254	223	196	1482
Cash Flow from Operating Activities	1613	1378	1970	2524	3263	2144	1803	2870	2984	3570	2811
Cash Flow from Investing Activities	-1888	-1446	-1694	-2265	-2039	-1840	-1488	-773	-492	-2266	-2639
Cash Flow from Financing Activities	389	-157	-24	-433	-1700	-369	-444	-2133	-2516	-30	-242
Net Cash Inflow / Outflow	113	-225	251	-174	-477	-65	-129	-35	-24	1275	-70
Closing Cash & Cash Equivalent	736	520	862	583	492	378	254	223	196	1482	1485

Dr. Reddy's Lab Ratios

#	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Earnings Per Share (Rs)	76.7	89.92	115.35	137.11	124.89	77.93	57.04	117.47	121.9	117.28	131.16
CEPS(Rs)	107.25	122.32	153.39	181.71	178.58	137.74	119.86	185.83	191.88	191.13	201.18
DPS(Rs)	13.75	15	18	20	20	20	20	20	25	25	30
Book NAV/Share(Rs)	290.91	371.04	457.33	572.92	731.49	734.72	752.35	840.01	932.31	1052.59	1145.98
Core EBITDA Margin(%)	24.75	22.72	24.08	23.13	23.03	17.41	16.46	20.57	14.1	20.32	17.49
EBIT Margin(%)	19.47	18.96	20.74	19.92	18.89	11.39	10.01	15.7	11.33	15.65	14.65
Pre Tax Margin(%)	18.31	18.09	19.61	19.19	18.36	10.94	9.46	15.12	10.76	15.14	14.21
PAT Margin (%)	13.2	12.76	14.55	15.47	13.54	8.86	6.39	12.62	11.57	10.25	10.13
Cash Profit Margin (%)	18.46	17.36	19.34	20.5	19.57	16.09	13.93	19.97	18.21	16.7	15.54
ROA(%)	12.99	12.46	13.47	13.67	11.05	6.14	4.23	8.86	9.2	8.21	8.08
ROE(%)	29.15	27.18	27.88	26.63	18.95	10.2	7.4	14.75	13.76	11.82	11.93
ROCE(%)	26.24	24.83	25	22.7	19.55	9.77	8.21	13.66	11.12	15.49	14.59
Receivable days	79.59	87.19	87.97	89.72	96.43	101.86	100.33	94.98	93.92	95.74	98.6
Inventory Days	65.6	62.74	62.06	60.27	60.11	69.56	73.63	74.03	71.52	77.11	81.57
Payable days	98.85	89.38	102.27	84.85	86.14	96.95	108.04	109.69	95.02	100.14	99.98
PER(x)	22.93	19.64	22.2	25.43	24.3	33.78	36.51	23.62	25.57	38.5	32.83
Price/Book(x)	6.05	4.76	5.6	6.09	4.15	3.58	2.77	3.3	3.34	4.29	3.76
Dividend Yield(%)	0.78	0.85	0.7	0.57	0.66	0.76	0.96	0.72	0.8	0.55	0.7
EV/Net Sales(x)	3.2	2.66	3.41	4.12	3.51	3.39	2.76	3.22	3.07	3.99	3.37
EV/Core EBITDA(x)	12.23	11.02	13.28	16.42	14.08	18.22	15.71	14.13	17.41	18.29	17.08
Net Sales Growth(%)	30.91	21.2	12.78	11.99	3.63	-8.81	0.6	8.17	13.39	8.74	13.11
EBIT Growth(%)	57.89	18.27	23.35	7.5	-2.24	-45.02	-11.62	69.65	-18.18	50.23	5.93
PAT Growth(%)	30.23	17.36	28.58	19.01	-9.79	-40.35	-27.43	113.72	3.9	-3.67	11.83
EPS Growth(%)	29.93	17.23	28.28	18.87	-8.92	-37.6	-26.81	105.96	3.77	-3.79	11.83
Debt/Equity(x)	0.66	0.58	0.58	0.44	0.27	0.4	0.41	0.28	0.14	0.17	0.18
Current Ratio(x)	1.52	1.51	1.78	1.74	1.86	1.15	1.52	1.88	1.75	1.79	1.82
Quick Ratio(x)	1.1	1.12	1.37	1.36	1.46	0.81	1.1	1.31	1.26	1.23	1.3
Interest Cover(x)	16.81	21.73	18.34	27.58	35.61	25.51	18.14	27.27	20.18	30.73	32.96
Total Debt/Mcap(x)	0.11	0.12	0.1	0.07	0.06	0.11	0.15	0.08	0.04	0.04	0.05

Dr. Reddy's Lab Shareholding Pattern

#	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023
Promoter	26.73	26.74	26.73	26.72	26.72	26.72	26.71	26.71	26.7	26.7
FII	29.13	29.03	29.04	27.76	27.42	25.16	25.87	26.26	27.29	27.25
DII	14.73	14.9	15.74	21.4	22.29	24.78	25.19	24.7	23.38	23.05
Public	16.29	17.13	16.4	12.07	12.04	12.12	11.87	12.26	12.1	11.7
Others	13.12	12.21	12.09	12.05	11.53	11.23	10.37	10.08	10.53	11.3
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023
Promoter	4.45	4.45	4.45	4.45	4.45	4.45	4.45	4.45	4.45	4.45
FII	4.85	4.83	4.83	4.62	4.56	4.19	4.31	4.37	4.54	4.54
DII	2.45	2.48	2.62	3.56	3.71	4.12	4.19	4.11	3.89	3.84
Public	2.71	2.85	2.73	2.01	2	2.02	1.98	2.04	2.01	1.95
Others	2.18	2.03	2.01	2	1.92	1.87	1.73	1.68	1.75	1.88
Total	16.63	16.63	16.64	16.64	16.64	16.64	16.64	16.65	16.65	16.65

Pros

Debtor days have improved from 100.14 to 99.98days.
Company has reduced debt.
Company is almost debt free.

Cons

Promoter holding is low: 26.7%.
Company has a low return on equity of 13% over the last 3 years.
Stock is trading at 3.4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.